Results 281 to 290 of about 113,026 (293)

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Lancet, The, 2018
Arun J Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri   +2 more
exaly  

Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees

Lancet, The, 2016
Kate A Dolan, Andrea L Wirtz, Babak Moazen   +2 more
exaly  

Alcoholic Hepatitis

JAMA: The Journal of the American Medical Association, 1968
openaire   +1 more source

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet, The, 2018
Mary E Rinella, Manal F Abdelmalek, Mustafa R Bashir   +2 more
exaly  

Targeting metabolic dysregulation for fibrosis therapy

Nature Reviews Drug Discovery, 2019
Xiao Zhao, Jennifer Yin Yee Kwan, Kenneth W Yip   +2 more
exaly  

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Lancet, The, 2016
Matthew Armstrong, Piers Gaunt, Guruprasad P Aithal   +2 more
exaly  

Autoimmune hepatitis

Nature Reviews Disease Primers, 2018
Giorgina Mieli-Vergani, Diego Vergani, Albert J Czaja   +2 more
exaly  

Primary Liver Cancer in Cirrhosis of the Alcoholic

Ca-A Cancer Journal for Clinicians, 1964
exaly  

ALCOHOLIC HEPATITIS

Medical Journal of Australia, 1962
openaire   +1 more source

Prevalencia de hepatitis A y hepatopatías crónicas: un reto a desarrollar

Atencion Primaria
exaly